Barclays on AstraZeneca (AZN): Acquisition of AMLN Makes Strategic Sense but High Price Tag
Tweet Send to a FriendGet Alerts AZN Hot Sheet
Price: $52.08 --0%
Rating Summary:
2 Buy, 7 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 13
Rating Summary:
2 Buy, 7 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 13
Trade AZN Now!
Barclays maintains an 'Equalweight' on AstraZeneca (NYSE: AZN) price target of GBP31.50.
Analyst, Mark Purcell, said, "Joint pleasure and pain in winning Amylin (Nasdaq: AMLN) bid: Bristol-Myers Squibb (NYSE: BMY) and AZN team up to acquire Amylin for $31/share, AZN paying BMS $3.4bn to participate. The deal will be earnings dilutive for AZ in '12 and '13 and given the lack of cost synergy scope in the diabetes space appears to be an expensive investment in the potential of Amylin's Byetta/Bydureon ex-US, although any potential valuation dilution would seem limited to around 60p/share (2%) in the absence of any synergies at all."
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $44.75 yesterday, with a 52 week range of $39.72-$51.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Mark Purcell, said, "Joint pleasure and pain in winning Amylin (Nasdaq: AMLN) bid: Bristol-Myers Squibb (NYSE: BMY) and AZN team up to acquire Amylin for $31/share, AZN paying BMS $3.4bn to participate. The deal will be earnings dilutive for AZ in '12 and '13 and given the lack of cost synergy scope in the diabetes space appears to be an expensive investment in the potential of Amylin's Byetta/Bydureon ex-US, although any potential valuation dilution would seem limited to around 60p/share (2%) in the absence of any synergies at all."
For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.
Shares of AstraZeneca closed at $44.75 yesterday, with a 52 week range of $39.72-$51.18.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
- Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
- Topeka Capital Upgrades Pacific Sunwear of California (PSUN) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Barclays, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
